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Abstract 
Background. Calcineurin inhibitors (CNIs) and direct oral anticoagulants 
(DOACs) share certain metabolic pathways, but whether DOACs 
influence CNI exposure has not been assessed. 







Methods. A single-center retrospective analysis was performed including 
39 organ recipients treated with the combination of a CNI and 
rivaroxaban (n = 29) or apixaban (n = 10). Dose-corrected CNI trough 
concentrations (C0/D) during 200 days before and after DOAC initiation 
were recorded (n = 261), together with covariates known to influence CNI 
disposition such as steroid dose and hematocrit. The average C0/D 
before and during DOAC therapy was compared using paired samples t-
test. Multivariable mixed models were constructed to estimate the effect 
of DOAC and other predictors on C0/D at each time point. 
Results. Group average C0/D was not significantly different before and 
during DOAC therapy for any CNI–DOAC combination (p = 0.089–
0.761), although C0/D changed >20% in 19/39 patients (13 increases, 6 
decreases). In multivariable analysis, independent predictors of 
tacrolimus C0/D were methylprednisolone dose (p = 0.039) and 
concomitant use of a CYP3A inhibitor (p = 0.007). The subgroup analysis 
per DOAC showed a limited but significant effect of rivaroxaban on 
tacrolimus C0/D (9.2% increase, p = 0.042). Independent predictors of 
ciclosporin C0/D were age (p = 0.018) and use of any DOAC (12.1% 
increase, p = 0.020). 
Conclusions. Apixaban, and particularly rivaroxaban, may cause a 
limited (<20%) increase in CNI trough concentration, an effect that is 
unlikely to trigger a dose change. It may be prudent to perform an 







additional CNI trough concentration measurement five to seven days 
after DOAC initiation, but pre-emptive CNI dose changes are not 
warranted based on these observations. 
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Introduction 
A significant proportion of transplant recipients requires temporary 
or long-term systemic anticoagulation, mainly as a result of atrial 
fibrillation, deep venous thrombosis, or pulmonary embolism.1–3 Vitamin 
K antagonists (VKAs) have historically been the standard of care for 
long-term anticoagulation in solid organ recipients, similar to the general 
population. Over the last years, however, several direct oral 
anticoagulants (DOACs) including dabigatran, rivaroxaban, and apixaban 
have become available. These are an attractive option because they are 
efficient, safe, and do not need to be systematically monitored.4,5 
However, clinicians may be reluctant to use them in transplant recipients 
because data regarding their use in this specific population are scarce. 
Furthermore, DOACs and the calcineurin inhibitors (CNIs) tacrolimus and 
ciclosporin share certain metabolic pathways that could raise concerns 
over potential bi-directional drug interactions. 







The CNIs tacrolimus and ciclosporin are substrates of the 
cytochrome P450 iso-enzymes 3A4 and 3A5 (collectively referred to as 
CYP3A) and the efflux pump P-glycoprotein (P-gp or ATP-binding 
cassette subfamily B member 1 (ABCB1), encoded by the multidrug-
resistance-1 gene (MDR1)). CYP3A and P-gp are present in the intestine 
(where they limit oral bioavailability) and the liver (where CYP3A 
metabolizes the great majority of circulating CNI and P-gp facilitates 
biliary excretion of the CNI and its metabolites).6 Inhibitors of CYP3A 
and/or P-gp will result in an increased exposure to CNIs, commonly 
assessed by the measurement of blood concentration (either as area 
under the time curve (AUC) or as trough concentration measurement). 
Tacrolimus and ciclosporin are themselves in vitro inhibitors of CYP3A 
and P-gp, although this is probably only clinically relevant for ciclosporin, 
which is a potent P-gp inhibitor and moderate CYP3A4 inhibitor.7,8 All 
three abovementioned DOACs are also substrates for P-gp, but the 
contribution of CYP enzymes to their disposition is more variable. 
Dabigatran is not metabolized by any CYP450 enzyme in vitro. CYP3A4 
and CYP2J2 account for approximately 18% and 14% of total 
rivaroxaban elimination,9 whereas apixaban is mainly metabolized by 
CYP3A.10 Some of the most studied combined P-gp/CYP3A inhibitors 
include ketoconazole and verapamil, which increase the exposure of all 
DOACs. There is no evidence that DOACs exert an effect on P-gp or 







CYP3A based on in vitro data and/or studies in limited numbers of 
healthy volunteers (in the case of rivaroxaban).11 Whether this remains 
true in a clinical context has not been assessed. The aim of this study, 
therefore, was to evaluate whether DOAC therapy influences CNI 
exposure in transplant recipients to a clinically relevant degree. 
 
Materials and methods 
Study design and population 
This was a single-center retrospective cohort analysis. The 
electronic hospital pharmacy billing and prescription records were 
queried to identify transplant patients who had been prescribed a CNI 
(tacrolimus [Prograft® or Advagraf®, Astellas Pharma, London, UK] or 
ciclosporin [Neoral®, Novartis, Basel, Switzerland]) together with a 
DOAC (dabigatran [Pradaxa®, Boehringer Ingelheim, Ingelheim, 
Germany], rivaroxaban [Xarelto®, Bayer, Leverkusen, Germany], or 
apixaban [Eliquis®, Bristol-Myers Squibb, New York, US]). Inclusion 
criteria were (1) concomitant administration of a CNI and a DOAC during 
at least seven days, (2) availability of at least two CNI trough 
concentrations before and at least one trough concentration during (and 
at least three days after the initiation of) concomitant DOAC therapy. 
Exclusion criteria were (1) less than seven days’ concomitant 
administration of CNI and DOAC and (2) initiation of a CYP3A 







inhibitor/inducer around the time DOAC initiation so that the individual 
effect of the DOAC could not be determined. CYP3A inhibitors/inducers 
were classified as moderate or strong based on the Food and Drug 
Administration classification of their in vivo inhibitory/inductive potency.12 
In- and outpatient CNI trough concentrations were registered between 
200 days before and 200 days after DOAC initiation. All trough 
concentrations were corrected for CNI daily dose (using the dose taken 
the day before trough concentration measurement). Hematocrit, 
methylprednisolone dose, use of concomitant CYP3A inhibitor/inducer, 
and weight were registered at the time of every trough concentration 
determination. Changes in CNI C0/D >20% (increase or decrease) were 
(arbitrarily) considered significant, as changes <20% are unlikely to result 
in a dose change by the treating physician. Estimated glomerular 
filtration rate (eGFR) was calculated using the MDRD formula.13 Hepatic 
dysfunction was defined as serum alanine aminotransferase more than 
three times the upper limit of normal, total bilirubin >2 mg/dl or known 
hepatic cirrhosis. Adverse events (such as bleeding) were identified by 
chart review. As this was a retrospective analysis of anonymously 
reported, routinely collected clinical information, an informed consent and 
approval by the ethics committee were not pursued. 
 
 








Data are presented as mean ± standard deviation except when 
stated otherwise. Normality was tested using the Shapiro-Wilk test. C0/D 
was not normally distributed and log-transformed for analysis 
[Ln(C0/D+1)]. C0/D ratios of tacrolimus and ciclosporin were always 
analyzed separately. CNI C0/D ratios before and during DOAC therapy 
were compared in two ways. First, average C0/D in the last 100 days 
before and the first 100 days after the initiation was calculated and 
compared using paired samples t-test. Analyses were repeated using the 
average of the last three C0/D ratios before and the first three C0/D 
ratios after DOAC initiation, which yielded virtually identical results and is 
not further reported. Second, all available C0/D ratios were entered in a 
linear mixed model to take into account the correlation between C0/D 
ratios in each patient and to allow modeling of time-related C0/D 
variability. A linear mixed model with random intercepts and a first-order 
autoregressive covariance structure was used to estimate the effect of 
covariates on CNI C0/D. The following variables were considered as 
possible fixed effect predictors of C0/D: gender, age, methylprednisolone 
dose, use of DOAC, type of DOAC, DOAC dose, use of concomitant 
CYP3A inhibitor, years post-transplantation, hepatic dysfunction, eGFR, 
and hematocrit. Weight was not considered as a predictor because it 
was only sporadically registered. Calculation of estimates was based on 







the restricted maximum likelihoods. In the final mixed model, we only 
included those terms that were statistically significant using F test and 
improved the model according to Akaike’s information criterion (AIC). 
Intra-patient variability of all available C0/D ratios in the 100 days before 
DOAC initiation was calculated as coefficient of variability (standard 
deviation/mean CNI C0/D) × 100%. Intra-patient variability could only be 
calculated for 30 patients, as 9 patients did not have sufficient C0/D 
ratios to calculate a standard deviation. A two-sided p-value <0.05 was 
considered statistically significant. For collinearity diagnostics, a variance 
inflation factor of >5 was considered indicative of multicollinearity. All 
analyses were performed using IBM SPSS Statistics version 22 (IBM, 
NY, USA). Figures were generated using Graphpad Prism version 6 




Sixty-seven patients were identified that had been concomitantly 
treated with a CNI and a DOAC between January 2012 and May 2016. 
Of these, 28 were excluded because the DOAC had been given less 
than 14 days (n = 4), insufficient CNI trough concentrations were 
available (n = 20), or a potent CYP3A inhibitor was initiated together with 
the DOAC and not stopped before DOAC cessation (n = 3). Only one 







patient was treated with dabigatran and was not included in the analysis. 
Demographics of the final study population are presented in Table 1. Of 
29 tacrolimus-treated patients, 22 received rivaroxaban (total of 149 
trough concentrations of which 77 were during co-treatment), and 7 
apixaban (43 trough concentrations, 18 during co-treatment). Of 10 
ciclosporin-treated patients, 7 received rivaroxaban (43 trough 
concentrations, 20 during co-treatment) and 3 received apixaban (26 
trough concentrations, 14 during co-treatment). Four patients were 
treated with a moderately strong CYP3A inhibitor at the time of at least 
one of the included CNI trough concentrations: three with amiodarone 
and one with fluconazole. No other CYP3A and/or P-gp inhibitors and 
inducers were registered. Hepatic dysfunction was present in one 
patient. 
 
C0/D before and during DOAC therapy 
Average C0/D was not significantly different before and during 
DOAC therapy for any CNI–DOAC combination (p = 0.089–0.761) as 
shown in Figure 1. Because stable group averages may obscure 
changes in C0/D that occur in individual patients, the latter are plotted in 
Figure 2. Significant (>20%) changes in C0/D occurred in 13/22 patients 
in the tacrolimus–rivaroxaban group (9 increases, 4 decreases), 3/9 in 
the tacrolimus–apixaban group (1 increase, 2 decreases), 2/7 in the 







ciclosporin–rivaroxaban group (2 increases), and 1/3 in the ciclosporin–
apixaban group (increase). In each of these subgroups of patients in 
which C0/D significantly changed, average CNI dose was not 
significantly different after DOAC initiation (data not shown). Only a trend 
was noted in tacrolimus–rivaroxaban co-treated patients in whom C0/D 
increased after rivaroxaban initiation (n = 9), where the average 
tacrolimus dose was 1.12 ± 1.45 mg/dl lower after rivaroxaban initiation 
(p = 0.066). This indicates that, on average, physicians accepted the 
alteration in exposure and did not change CNI dose. For clarification, the 
three subgroups of C0/D evolution (stable, increase, and decrease) in 
tacrolimus–rivaroxaban co-treated patients are plotted separately in 
Figure 3. The ratio between the average C0/D before and after DOAC 
initiation was positively correlated with the degree of intra-patient 
variability in pre-DOAC C0/D ratios (Pearson correlation coefficient 
0.445, p = 0.014), indicating that patients with high baseline variability in 
CNI exposure were also more likely to display a significant change in 
exposure between the pre- and post-DOAC phases. 
 
Determinants of C0/D over time 
As the abovementioned comparison of C0/D values before and 
during DOAC therapy does not take into account other covariates known 
to influence CNI pharmacokinetics (patient age, time after 







transplantation, hematocrit [particularly for tacrolimus], steroid dose, 
concomitant use of other CYP3A inhibitors/inducers and hepatic 
dysfunction)6 or time-related variability and correlations between C0/D 
ratios in individual patients, a linear mixed model analysis was 
performed. The results of this analysis are presented in Table 2. 
Significant predictors of C0/D in tacrolimus-treated patients were the 
intercept (indicating significant differences between patients), 
methylprednisolone dose, and use of concomitant CYP3A inhibitor, but 
not DOAC use. Figure 4 is a scatterplot of tacrolimus C0/D by 
methylprednisolone dose, which further illustrates their significant 
correlation. In ciclosporin-treated patients, predictors were age and 
DOAC use. The estimated effect of DOAC use in ciclosporin-treated 
patients was a 12.1% (95% CI, 2.1-22.2%) increase in C0/D. 
In the abovementioned analysis, rivaroxaban and apixaban were 
grouped into one predictor variable; separate analyses for each 
combination of CNI and DOAC are presented in Tables S1-2 
http://links.lww.com/TDM/A176. Here, DOAC use was a significant 
predictor of C0/D in the tacrolimus–rivaroxaban group and borderline 
significant in the ciclosporin–rivaroxaban group (estimated effects 0.092 
(0.003-0.180), p = 0.042 and 0.127 (0.010-0.265), p = 0.068; 
respectively). This corresponds with a 9.2–12.7% estimated increase in 
C0/D related to rivaroxaban use after correction for steroid dose, time, 







and concomitant use of other CYP3A inhibitors. Hematocrit was not 
predictive of C0/D in this analysis. 
 
Safety 
The average follow-up period under concomitant CNI–DOAC 
therapy was 34 months, during which time bleeding events were 
registered in two patients. One patient with a suprapubic catheter on 
tacrolimus–apixaban had a single episode of macroscopic hematuria that 
remained unexplained. One patient on tacrolimus–rivaroxaban had 
repetitive episodes of macroscopic hematuria related to bladder lithiasis, 
for which she received endoscopic treatment. DOAC treatment was 
continued in both patients. 
 
Discussion 
This study indicates a possible effect of the DOACs rivaroxaban 
and apixaban on CNI disposition that is, however, unlikely to be clinically 
relevant. Group average C0/D ratios were similar before and during 
DOAC therapy. Although C0/D evolution differed considerably between 
individual patients, there was no clear pattern. Both increased CNI C0/D 
(which would occur if DOACs inhibited CYP3A and/or P/-gp) and 
decreased CNI C0/D (which would occur if DOACs induced CYP3A 
and/or P/gp) occurred. There was a strong positive correlation between 







pre-DOAC intra-patient variability in CNI exposure and the change in CNI 
exposure after DOAC initiation. This suggests that a strongly altered 
C0/D after DOAC initiation is often simply a reflection of high pre-existing 
time-related variability in exposure in that patient, whatever the 
underlying cause. Finally, after correcting for variables known to 
influence CNI disposition in mixed model analysis, only rivaroxaban was 
associated with a 9.2% increase in C0/D of tacrolimus (p = 0.042) and a 
12.7% increase in C0/D of ciclosporin (not significant at p = 0.068). We 
note that, for a stable dose, a 12.7% change in C0/D also implies a 
12.7% change in trough concentration. This is unlikely to be clinically 
relevant. Most changes in drug exposure of <20% are considered to be 
well within the range of biological variability and, even in the case of 
CNIs, will generally not justify a dose change. However, it is important to 
note that susceptibility to drug–drug interactions (DDIs) varies 
considerably between individuals. For example, ciclosporin increased 
repaglinide AUC 2.4-fold on average in healthy volunteers, but the range 
was 1.2- to 5.3-fold and was partly genetically determined.14 The 
absence of a systematic effect does not exclude an interaction in 
individual patients, which is why it does not suffice to compare group 
average trough concentrations or C0/D ratios. For the same reason, 
studies using limited numbers of healthy volunteers can be used to 
confidently exclude a major interaction but do not obviate the need for 







post marketing DDI surveillance. Some patients might still be 
predisposed to engage in moderate interactions, which may necessitate 
dose changes for drugs with a narrow therapeutic index such as CNIs. In 
the case of CNIs and DOACs, this study is in line with preclinical data10,11 
suggesting that if DOACs have an effect on CNI disposition, it will likely 
be irrelevant in most (but not necessarily all) patients. 
This study has limitations. First, it is a retrospective analysis of 
clinical data from a relatively limited number of patients that received 
different types of transplants. Several potential sources of variability 
(e.g., noncompliance, diarrhea) were not systematically registered and 
could therefore not be accounted for. On the other hand, the clinical 
factors that influence CNI disposition in organ recipients are well 
characterized and most were corrected for in the mixed model analysis. 
Although this is a thorough way of analyzing longitudinal clinical data, it 
cannot circumvent the inherent limitations of the dataset and must be 
considered complementary to controlled pharmacokinetic studies 
(generally performed in healthy volunteers). Second, it would have been 
interesting to include genotype information, as there is some evidence 
that certain genetic polymorphisms (e.g., CYP3A5*1) may diminish the 
impact of CYP3A inhibitors on tacrolimus disposition.15,16 Third, this study 
could not address the potential effect of CNIs on DOACs, since DOAC 
trough concentration monitoring was performed only sporadically. As 







ciclosporin is a combined inhibitor of CYP3A and P-gp, it is expected to 
strongly increase the exposure to all three major DOACs resulting in an 
increased risk of bleeding, as has been demonstrated for rivaroxaban.17 
Finally, for C0/D to be a valid reflection of dose requirement, 
pharmacokinetic steady state has to be assumed. This may not have 
been the case for all collected values if, for example, doses had been 
very recently changed. However, the same is true for trough 
concentrations that correlate best with drug exposure in steady-state 
conditions and will also vary as a result of dose changes, whereas C0/D 
does not. AUC’s are the preferred way to assess changes in exposure 
but were not available. Furthermore, tacrolimus AUC correlates well with 
C0 (r = 0.83-0.94).18 
 
Conclusion 
In conclusion, rivaroxaban and apixaban do not seem to have a 
clinically relevant effect on CNI disposition in organ recipients. It may be 
prudent to perform an additional CNI trough concentration measurement 
five to seven days after DOAC initiation in order to quickly detect the 
individual patient suffering from significant DOAC-induced changes in 
CNI exposure. Preemptive CNI dose changes are not warranted based 
on these results. 
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Average calcineurin inhibitor dose-corrected trough concentrations 
before and during therapy with oral anticoagulants 
C0/D, dose-corrected trough concentration; DOAC, direct oral 
anticoagulant 
Figure 2 
Average calcineurin inhibitor dose-corrected trough concentrations 
before and during therapy with oral anticoagulants, individual patient 
values. 
C0/D, dose-corrected trough concentration 
Figure 3 
Average tacrolimus dose-corrected trough concentrations before and 
during therapy with rivaroxaban, by category. 
C0/D, dose-corrected trough concentration 
Figure 4 
Scatterplot of all tacrolimus dose-corrected trough concentrations by 
methylprednisolone dose. 
C0/D, dose-corrected trough concentration 





Table 1. Patient characteristics 
Characteristic Value 
Type of transplant (n)  
Kidney 18 
Lung 13 
Kidney + lung 2 
Heart 5 
Allogenic stem cell 1 
Gender (male/female) 22/17 
Age (years)a 63.8 ± 12.8 
Caucasian ethnicity  37 (95%) 
Time after transplant (years)a 9.1 ± 9.5 
Calcineurin inhibitor (n)  
Tacrolimus 29 
Cyclosporine 10 
Oral anticoagulant  
Rivaroxaban 29 
Apixaban 10 
Other immunosuppressants (n)  
Mycophenolate mofetil 25 
Azathioprine 5 
Methylprednisolone 28 
Methylprednisolone dose (mg/day)b  
Average  5.9 ± 7.7 
Range 0–48 
Concomitant use of CYP3A inhibitor (n) 4 
Hematocrit (%)b 37.6 ± 5.4 
Number of available CNI trough concentrations per 
patient (n) 
6.7 ± 1.8 
Trough concentration (ng/ml)b  
Tacrolimus 9.5 ± 3.1 
Ciclosporin 105.0 ± 32.6 
C0/D ratio (ng/ml/mg)b  
Tacrolimus 2.5 ± 1.3 
Ciclosporin 0.9 ± 0.4 
aAt the initiation of oral anticoagulant 
bConsidering all available values at all time points 
C0/D, dose-corrected trough concentration 





Table 2. Multivariable mixed model estimates for fixed effect predictors of calcineurin 
inhibitor dose-corrected trough concentrations  
Tacrolimus Ciclosporin 
Parameter Estimated 
effect 95% CI p 
Estimated 
effect 95% CI p 
Intercept 1.452 1.236-1.669 <0.001
a
 - - 0.925a 
Methylprednisolone 




 - - 0.130 
Concomitant CYP3A 








transplantation (days) - - 0.174
a
 - - 0.175a 
Age (years) - - 0.893 0.009 0.002-0.017 0.018
a
 
DOAC use - - 0.329 0.121 0.021-0.222 0.020
a
 
aVariables included in the final model. 
bNo cases 
CI, confidence interval; DOAC, direct oral anticoagulant 
The endpoint of C0/D (dose-corrected trough concentration) is log-transformed. A 
one-point increase in a predictor value will result in a [(eB)-1] × 100% increase in 
C0/D, where B is the estimated effect. For example, tacrolimus C0/D is expected to 
decrease 0.7% per 1 mg increase in methylprednisolone dose, and DOAC use is 
associated with a 12.1% increase in ciclosporin C0/D. This method of reporting was 
chosen because back-transformed effects would relate to absolute (ng/ml/mg) 
changes in C0/D, which were considered less relevant than relative (%) changes. 
 




















 Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
